Baclofen for Alcohol Use Disorder
Baclofen is a GABA-B medication used off-label for alcohol use disorder that may ease craving and anxiety, though the evidence is genuinely mixed. Its clearest niche is advanced liver disease since the liver barely processes it, so it is not first-line and must never be stopped abruptly.
Battling addiction & ready for help?
What Is Baclofen and How Might It Help Drinking?
Baclofen is a muscle relaxant that has been used for decades to ease spasticity, and over the past twenty years it has drawn serious attention as a possible treatment for alcohol use disorder. If you are weighing it for yourself or someone you love, the straight starting point is this: baclofen is not approved by the FDA for drinking problems, it is not a first-line treatment anywhere, and the evidence for it is genuinely mixed. Yet for a specific group of people, especially those with advanced liver disease, it remains a real option worth discussing with a doctor.
The reason researchers got curious is chemistry. Baclofen activates GABA-B receptors, part of the same calming system that alcohol itself engages[1][2][3]. In animal studies that switch dampens dopamine release in the brain’s reward circuitry, the system behind craving and the reinforcing pull of a drink[1]. In plain terms, the theory is that baclofen may turn down the volume on wanting to drink, and it may also calm the anxiety that so often rides alongside alcohol dependence[2].
That is a plausible mechanism, not a settled cure. What follows is a straight account of where the evidence actually stands, who baclofen tends to be considered for, and the safety points that matter most, including the one that surprises people: baclofen must never be stopped suddenly.
Baclofen plus alcohol can slow breathing dangerously, and stopping baclofen abruptly can trigger seizures. Call 911 for trouble breathing; call or text 988 for a crisis. Never stop baclofen cold on your own.
What to do:
- Call 911 for slow or shallow breathing, a person you cannot fully wake, or a seizure. These can follow baclofen taken with alcohol or at high doses.
- If you are thinking about suicide or you are in danger right now, call or text 988 (Suicide and Crisis Lifeline), any time.
- Do not stop baclofen abruptly. Suddenly quitting baclofen can itself cause severe withdrawal and seizures within a few days, so any change needs a doctor’s tapering plan[4].
- Do not quit heavy daily drinking alone either. Sudden alcohol withdrawal can cause seizures and delirium; a supervised medical detox handles both risks safely. Find alcohol detox and treatment →
- Off-label in the U.S.: baclofen is not FDA-approved for alcohol use disorder and is prescribed off-label; France is the only country to have formally approved it, in 2018[3][5].
- A modest, mixed signal: a 2023 Cochrane review of 17 trials and 1,818 people found baclofen probably lowers relapse risk (RR 0.87) and raises abstinent days (about 9 more days), but does not reliably cut heavy drinking[6].
- A real niche in liver disease: baclofen is cleared mainly by the kidneys and barely processed by the liver, so it draws interest when liver damage limits other medicines[2][7].
- Never stop it suddenly: abrupt discontinuation can cause severe withdrawal, delirium, and seizures, typically within one to four days[4].
How Baclofen May Reduce Craving and Anxiety
Understanding the proposed mechanism helps explain both the excitement around baclofen and why results have been inconsistent. Unlike a medication that punishes drinking, baclofen is thought to quiet the underlying drive.
Preclinical research suggests that switching on GABA-B receptors suppresses dopamine release in the mesolimbic reward system, the circuit central to craving and to the reinforcing high that keeps drinking going[1]. There is also evidence that baclofen may loosen the learned link between a drinking cue, the sight of a bar or the smell of beer, and the urge that follows, possibly through effects on the amygdala[1].
One more feature draws clinical interest. Because dependence often travels with anxiety, a medication that eases both could help two problems at once, and baclofen’s calming action is a plausible reason it might reduce the anxiety tied to alcohol dependence[2]. That rationale is reasonable, but it has not been strongly proven in controlled trials focused on anxious drinkers, so it belongs in the “promising theory” column rather than the “established” one.
The Story That Started It
The modern use of baclofen for drinking traces back to one physician who tried it on himself. Dr. Olivier Ameisen, a French-American cardiologist with severe alcohol use disorder, published a case report in 2004 describing how high-dose baclofen ended his own cravings, and his 2008 memoir reached a wide audience and fueled intense patient advocacy in France[5].
Before any formal approval existed, more than 34,000 new patients in France started baclofen for alcohol dependence in a single year, prescribed by over 9,000 general practitioners trying it for the first time[8].
That groundswell is a documented case of patient demand outrunning the science. It drew attention to a treatment that might otherwise have been overlooked, but it also built a prescribing culture ahead of solid trial evidence, which complicated research and pressured regulators[5].
Does Baclofen Actually Work for Alcohol Use Disorder?
The candid answer is that it helps modestly, for some outcomes, in some people, and the trials disagree enough that no one should oversell it. The most complete evidence review available found baclofen probably reduces relapse and increases abstinent days, while doing little for other drinking measures[6].
The 2023 Cochrane review pooled 17 randomized trials covering 1,818 participants[6]. Compared with placebo, baclofen probably decreased the risk of relapse (relative risk 0.87, 95% CI 0.77 to 0.99) and increased the percentage of days abstinent by about 9 days (mean difference 9.07, 95% CI 3.30 to 14.85)[6]. It showed no clear benefit on heavy drinking days or on drinks per drinking day, and rates of side effects were similar to placebo[6]. A 2025 analysis from the French Alcohol Society reading that same review put it plainly: baclofen showed significant efficacy for maintaining abstinence, but not for reducing the amount people drank, and no dose-response relationship turned up[3].
The wrinkle is that an earlier review reached a cooler conclusion. The 2018 Cochrane review of 12 trials and 1,128 participants found no significant difference between baclofen and placebo on relapse (RR 0.88, 95% CI 0.74 to 1.04) or on days abstinent, and in two studies baclofen slightly increased drinks per drinking day[9]. Reading both together, baclofen may help some people hold onto abstinence, but the effect is modest and the certainty limited.
Trial Results at a Glance
Individual trials sharpen the picture, especially the way dose and patient type changed the outcome.
| Review or Trial | Who It Studied | Key Finding |
|---|---|---|
| 2023 Cochrane review | 17 trials, 1,818 participants | Relapse risk lower (RR 0.87, 95% CI 0.77 to 0.99); about 9 more abstinent days (MD 9.07)[6] |
| 2018 Cochrane review | 12 trials, 1,128 participants | No significant difference on relapse (RR 0.88, 95% CI 0.74 to 1.04) or abstinent days[9] |
| ALPADIR (France, 180 mg/day) | Detoxified patients | Abstinence 11.9% vs 10.5% for placebo, not significant; craving fell in the baclofen group[10] |
| BacALD (with or without liver disease, 30 to 75 mg/day) | 104 participants[11] | Days abstinent 43% placebo vs 69% (30 mg) vs 65% (75 mg)[11] |
Why Do the Trials Disagree?
A big part of the answer is dose. Across studies the daily dose ranged from as little as 10 mg to as much as 300 mg, and pooling trials that different has been compared to averaging results from separate drugs[9][7]. Populations differed too, from people still drinking at the start to those already detoxified, and baclofen’s abstinence benefit in the 2023 review held up most clearly among detoxified participants[6]. When trials test different doses in different people, mixed results are what you would expect.
The Low-Dose Versus High-Dose Debate
This is arguably the single most consequential unresolved question in baclofen’s story, because it shapes both how well the drug works and how risky it is.
The instinct behind high-dose treatment came from Ameisen’s account that very large doses were needed to reach “indifference,” and clinical data do show the effective dose varies enormously from one person to the next, with higher doses tending to track more severe addiction[1]. France ran with that idea, allowing individualized titration up to 300 mg per day, and in one large French cohort the longest-treated patients averaged more than 110 mg per day[12].
The trouble is that rigorous high-dose trials have not delivered. The ALPADIR study tested a target dose of 180 mg per day in detoxified patients and found no significant advantage over placebo for maintaining abstinence, though craving did fall in the baclofen group[10]. And when researchers compared doses head to head, the higher end fared worse, not better.
A meta-analysis comparing dose ranges found that low-dose baclofen, in the range of 30 to 60 mg a day, showed better efficacy than high-dose regimens, and that tolerability of high-dose baclofen was poor[13].
Put together, the evidence leans toward modest, lower doses rather than aggressive escalation. Commonly studied fixed doses sit around 30 to 80 mg per day[7], the BacALD trial found benefit at just 30 and 75 mg[11], and no clear dose-response emerged in the most recent pooled analysis[3]. Above the lower range the efficacy evidence thins while safety concerns grow, which is worth knowing before agreeing to a high-dose plan.
Where Baclofen Stands Out in Liver Disease
Here is the genuine niche, the situation where baclofen moves from also-ran to serious contender. For someone whose liver is already damaged by years of drinking, the usual medications become hard to use, and baclofen’s chemistry sidesteps the main problem.
The FDA-approved options each run into the liver. Disulfiram can be toxic to it and is generally avoided in significant liver disease, and naltrexone carries an FDA warning about liver injury that makes many specialists cautious in advanced disease[7]. Baclofen is different because it is excreted largely unchanged by the kidneys and undergoes little liver metabolism, which makes it useful precisely when hepatic function is impaired[2][7]. A liver that is struggling is less likely to let the drug build up to dangerous levels.
The liver-specific data are limited but point in an encouraging direction. A meta-analysis pooling 322 patients with alcohol use disorder and liver disease found an overall abstinence rate of 53%, though the two controlled trials within that pool showed no statistically significant edge over placebo, so the controlled evidence is still underpowered[14]. The BacALD trial, built to include people with alcoholic liver disease, remains the most rigorous read, with significantly more abstinent days on baclofen and a cautionary note from its authors that its role “might be best limited to specialist services,” partly because of one overdose in the 75 mg arm[11].
Real-world experience adds reassurance without settling the question. A French multicenter study followed 71 patients with alcohol-related cirrhosis, a quarter of whom had ascites, treated at a mean dose of 75 mg per day; declared drinking fell from 100.2 to 14.7 grams a day, 40.8% reached abstinence at 12 months, and no serious adverse events or overt encephalopathy were tied to baclofen, though drowsiness was common[15]. That is a meaningful safety signal in a fragile population, even without a comparison group.
Side Effects and the Withdrawal Risk You Must Know
Baclofen is not a gentle medication, and its risks deserve plain language. Most are manageable with the right dose and monitoring, but two, withdrawal on abrupt stopping and overdose with alcohol, are serious enough that they shape how the drug should be used.
Sedation is the most common effect and it tracks with dose. Drowsiness, fatigue, and dizziness show up across trials, and in an intensive-care study using 50 to 150 mg per day, delayed awakening occurred in 8.9% of baclofen patients compared with 1.9% on placebo[16]. Kidney function matters here too: because baclofen leaves the body through the kidneys, reduced kidney function raises blood levels and toxicity risk, which is why that trial adjusted every dose to kidney function[16].
| Risk | What to Know |
|---|---|
| Sedation and dizziness | The most common effects, worse at higher doses; delayed awakening hit 8.9% vs 1.9% on placebo in an ICU trial[16] |
| Abrupt-stop withdrawal | Suddenly quitting can cause severe psychiatric symptoms, delirium, agitation, and seizures, usually within 1 to 4 days[4] |
| Overdose, especially with alcohol | In toxicity cases, CNS depression occurred in 68%, seizures in 36%, and slowed breathing in 21%, mostly at doses of 300 mg or more[4] |
| Reduced kidney function | Raises baclofen blood levels and toxicity risk, so doses are adjusted for kidney function[16] |
The withdrawal point is the one most easily missed. Stopping baclofen suddenly, especially from higher doses, can set off severe withdrawal, with psychiatric disturbances, delirium, agitation, and seizures typically beginning within one to four days[4]. That is why baclofen has to be tapered under medical guidance rather than halted on impulse, and why anyone starting it should be told about this before the first pill.
Overdose is the other serious risk. A systematic review of baclofen toxicity and withdrawal found that, among the toxicity cases, CNS depression occurred in 68%, seizures in 36%, and respiratory depression in 21%, mostly at doses of 300 mg or higher, with about 54.5% needing a ventilator; reassuringly, 97.7% recovered fully[4]. The combination of baclofen and alcohol, common in someone who relapses, is especially dangerous, which is why breathing comes first in an emergency.
How Baclofen Compares With FDA-Approved Options
Three medications are approved by the FDA for alcohol use disorder, and baclofen is measured against them, not offered instead of them. For a full look at the approved options, see the dedicated guide to medications for alcohol use disorder.
| Medication | How It Works | Main Limitation |
|---|---|---|
| Naltrexone | Blocks opioid receptors, reducing alcohol’s pleasurable effect | Carries an FDA warning about liver injury, limiting use in advanced liver disease |
| Acamprosate | Eases withdrawal-related anxiety and craving | Dosed three times a day; more modest effect |
| Disulfiram | Causes an unpleasant reaction if alcohol is consumed | Generally avoided in significant liver disease; needs strong motivation |
| Baclofen (off-label) | Activates GABA-B receptors, easing craving and anxiety in some people | Weaker, mixed evidence; best dose and long-term safety uncertain |
Baclofen is not first-line anywhere. It comes up most often when the approved medicines are unsafe or have not worked, and its evidence base is weaker than naltrexone’s[7]. For the narrow situation of advanced liver disease with drinking that has not responded to other care, baclofen may be the least-bad available option, which is a different claim from “proven effective.”
Who Might Consider Baclofen for Drinking?
Three groups come up most in the clinical conversation, and in each the case rests on fit rather than on baclofen being broadly superior.
- People with liver disease who cannot safely use other medications. The most relevant data, from BacALD and the French cirrhosis cohort, support conservative dosing at or below 75 mg per day under specialist care, not high-dose self-titration[11][15].
- People who have not responded to naltrexone or acamprosate. A predictor analysis from BacALD found baclofen worked significantly better in patients who were drinking more heavily at the outset (hazard ratio for relapse 0.360, 95% CI 0.168 to 0.772), which hints that severity may help identify who responds[17].
- People with significant anxiety alongside their drinking, given baclofen’s calming action and its potential to ease the anxiety tied to dependence[2]. This is a reasonable rationale rather than a strongly proven one.
Whatever the group, the decision belongs in a candid conversation with a clinician. A person considering baclofen should understand that it is off-label, that the evidence is mixed, that the best dose is uncertain, that it carries real risks including withdrawal seizures if stopped abruptly, and that continued heavy drinking is itself life-threatening, which is part of why trying it can still be reasonable under close supervision.
The French Experience and Regulatory Status
France has by far the most eventful history with this drug, and it stands as the largest real-world test of baclofen for drinking. Off-label prescribing grew quickly after 2008, and in March 2014 the French medicines agency granted a Temporary Recommendation for Use that regulated prescribing and permitted individualized doses up to 300 mg per day[12][18]. In 2018 France went further and formally approved baclofen for alcohol dependence, the only country to do so, though the approval was framed around supporting reduced drinking rather than maintaining abstinence[5][3].
That large-scale use also surfaced a safety signal at high doses. In a French cohort of 165,334 patients, baclofen was associated with a higher risk of hospitalisation and death than the approved medications, with the risk of death rising with dose to a hazard ratio of 2.27 at the highest doses[18]. Set against trials that failed to show a high-dose benefit, that signal is a central reason high-dose baclofen remains contested, and why the French Alcohol Society’s more recent position argues for keeping baclofen available while updating the rules around it based on the best current evidence[3].
In the United States, baclofen remains off-label for drinking. The FDA has not approved it for this use and it is not part of major U.S. treatment guidelines, so a prescriber offering it here is making an off-label decision, which means documenting the reasoning, discussing alternatives, and monitoring closely are all part of responsible care.
Getting Help for Alcohol Use Disorder
If you have read this far weighing baclofen, hold onto the balanced picture. It is a promising option for some people, most clearly those with liver disease who cannot use the standard medications, and it is not a first-line treatment or a sure thing for anyone. The right move is to decide with a clinician who is candid about the uncertainty, checks your kidney and liver function, starts low, and has a tapering plan ready before the first pill.
Medication, whichever one fits, works best as part of real treatment rather than on its own. If you have been drinking heavily every day, the safest first step is a supervised detox rather than stopping cold, since alcohol withdrawal can be dangerous without support, followed by the counseling and medication that help sobriety last. Alcohol use disorder is a condition of the brain’s reward and stress systems, not a failure of character, and it responds to treatment.
To see how baclofen fits the wider set of choices and the road out:
- Compare the approved options in medications for alcohol use disorder
- Understand what ongoing heavy use does to the liver, in alcoholic liver disease
- See how a medically supervised process handles tapering off alcohol safely
- Check whether the pattern fits you, in am I an alcoholic
Frequently asked questions
Is Baclofen FDA-Approved for Alcohol Use Disorder?
No. In the United States baclofen is prescribed off-label for drinking problems, meaning the FDA has not approved it for this use and it is not part of major U.S. treatment guidelines. France is the only country to have formally approved baclofen for alcohol dependence, which it did in 2018, and even there the approval was framed around supporting reduced drinking[3][5]. Because it is off-label here, a prescriber offering it should document the reasoning, discuss alternatives, and monitor closely.
How Well Does Baclofen Work Compared to Placebo?
Modestly, and the trials disagree. A 2023 Cochrane review of 17 studies and 1,818 people found baclofen probably lowers relapse risk (relative risk 0.87) and raises abstinent days by about 9, but does not reliably reduce heavy drinking[6]. An earlier 2018 Cochrane review of 12 studies found no significant difference from placebo on relapse or abstinent days[9]. The fair reading is that baclofen may help some people maintain abstinence, but the effect is modest and far from guaranteed.
Why Is Baclofen Considered for People With Liver Disease?
Because of how the body clears it. Baclofen is excreted largely unchanged by the kidneys and undergoes little liver metabolism, so it is less likely to build up when the liver is damaged, unlike disulfiram and naltrexone, which raise liver-injury concerns[2][7]. In a French study of 71 patients with alcohol-related cirrhosis treated at about 75 mg a day, drinking fell sharply and no serious adverse events were tied to baclofen, though the evidence still supports conservative doses under specialist care rather than high-dose regimens[15].
Is a Higher Dose of Baclofen More Effective?
The evidence does not support that. A meta-analysis found low-dose baclofen, roughly 30 to 60 mg a day, worked better than high-dose regimens, and that high-dose tolerability was poor[13]. The rigorous ALPADIR trial tested a target of 180 mg a day in detoxified patients and found no significant benefit over placebo for maintaining abstinence[10]. A large French cohort also linked higher doses to a greater risk of hospitalisation and death, with the risk of death rising to a hazard ratio of 2.27 at the highest doses[18].
Can You Stop Taking Baclofen Suddenly?
No, and this is one of the most important safety points. Abruptly stopping baclofen, especially from higher doses, can cause severe withdrawal that includes psychiatric disturbances, delirium, agitation, and seizures, typically within one to four days[4]. Baclofen has to be tapered under medical guidance rather than halted on impulse. If a dose feels too sedating or something goes wrong, that is a reason to call the prescriber, not to quit cold.
What Happens if Baclofen Is Mixed With Alcohol?
The combination is dangerous because both deepen central nervous system depression. In a review of baclofen toxicity cases, CNS depression occurred in 68%, seizures in 36%, and slowed breathing in 21%, mostly at high doses, and about 54.5% needed a ventilator[4]. If someone is hard to wake or breathing slowly after taking baclofen and drinking, call 911. The risk is one reason baclofen for alcohol use disorder is managed carefully by a clinician, with a clear plan for what to do after a slip.
Get Treatment Help
If you or someone you love is struggling with addiction, getting help is just a phone call away, or consider trying therapy online with BetterHelp.
Exclusive offer: 20% Off BetterHelp*Following links to the BetterHelp website may earn us a commission that helps us manage and maintain AddictionHelp.com. *Get 20% off your first month of BetterHelp. Offer valid for new BetterHelp users only. Offer cannot be combined with insurance.
- Fact-Checked
- Editor
